C57BL/6JCya-Mycem1/Cya
Common Name
Myc-KO
Product ID
S-KO-03294
Backgroud
C57BL/6JCya
Strain ID
KOCMP-17869-Myc-B6J-VA
Status
When using this mouse strain in a publication, please cite “Myc-KO Mouse (Catalog S-KO-03294) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Myc-KO
Strain ID
KOCMP-17869-Myc-B6J-VA
Gene Name
Product ID
S-KO-03294
Gene Alias
Myc2, Nird, Niard, bHLHe39
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 15
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000022971
NCBI RefSeq
NM_010849.4
Target Region
Exon 2~3
Size of Effective Region
~4.3 kb
Overview of Gene Research
MYC, a proto-oncogene, consists of 3 paralogs: C-MYC, N-MYC, and L-MYC. It functions as a universal amplifier of transcription, regulating diverse cellular processes such as cell cycle, proliferation, metabolism, differentiation, and apoptosis [2,3,4,5]. MYC is frequently deregulated in human cancers, being dysregulated in approximately 70% of cases, and is involved in tumor initiation and maintenance, making it an appealing therapeutic target [1].
In vivo studies have shown that MYC inhibition leads to anti-proliferative effects and tumor regression while causing reversible changes in healthy tissue [1]. Some compounds that directly or indirectly inhibit MYC have demonstrated anticancer activity in preclinical tumor models [2]. Strategies for targeting MYC include inhibiting its binding to MAX, preventing its expression, and blocking genes with synthetic lethality upon MYC overexpression [2].
In conclusion, MYC is a key regulator of multiple cellular functions. The findings from in vivo studies on MYC inhibition highlight its potential as a therapeutic target in cancer treatment. Understanding MYC's role through such model-based research is crucial for developing effective cancer therapies.
References:
1. Llombart, Victor, Mansour, Marc R. 2021. Therapeutic targeting of "undruggable" MYC. In EBioMedicine, 75, 103756. doi:10.1016/j.ebiom.2021.103756. https://pubmed.ncbi.nlm.nih.gov/34942444/
2. Duffy, Michael J, O'Grady, Shane, Tang, Minhong, Crown, John. 2021. MYC as a target for cancer treatment. In Cancer treatment reviews, 94, 102154. doi:10.1016/j.ctrv.2021.102154. https://pubmed.ncbi.nlm.nih.gov/33524794/
3. Das, Subhendu K, Lewis, Brian A, Levens, David. 2022. MYC: a complex problem. In Trends in cell biology, 33, 235-246. doi:10.1016/j.tcb.2022.07.006. https://pubmed.ncbi.nlm.nih.gov/35963793/
4. Baluapuri, Apoorva, Wolf, Elmar, Eilers, Martin. 2020. Target gene-independent functions of MYC oncoproteins. In Nature reviews. Molecular cell biology, 21, 255-267. doi:10.1038/s41580-020-0215-2. https://pubmed.ncbi.nlm.nih.gov/32071436/
5. Jha, Rajiv Kumar, Kouzine, Fedor, Levens, David. 2023. MYC function and regulation in physiological perspective. In Frontiers in cell and developmental biology, 11, 1268275. doi:10.3389/fcell.2023.1268275. https://pubmed.ncbi.nlm.nih.gov/37941901/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.